Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a beta blocker presented as an oral dosage form for oral use. It is used to lower elevated blood pressure in adult patients with hypertension. It belongs to the class of selective β1‑adrenergic receptor antagonists and exhibits additional nitric‑oxide mediated vasodilatory activity, contributing to its antihypertensive effect.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Nebivolol is used in the management of cardiovascular conditions that involve elevated blood pressure.

Hypertension: reduces systolic and diastolic blood pressure by decreasing heart rate and promoting vasodilation.

Nebivolol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Acute bronchospasm or allergic reaction

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety.

- Monitor blood pressure: check regularly after initiation and dose adjustments. - Assess heart rate: watch for excessive bradycardia, especially in patients with conduction disorders. - Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may precipitate bronchospasm. - Adjust dose in renal impairment: reduced clearance may increase drug exposure. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and light.

Nebivolol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: additive negative chronotropic effects. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations. - Calcium‑channel blockers that affect AV nodal conduction (e.g., verapamil, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive response. - Diuretics: combined effect may cause pronounced hypotension. - Antidiabetic agents (insulin, sulfonylureas): nebivolol may mask hypoglycemia symptoms.